Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 7

Dabrafenib for treatment of BRAF-mutant melanoma

Authors Kainthla R, Kim K, Falchook G

Received 15 August 2013

Accepted for publication 9 October 2013

Published 31 December 2013 Volume 2014:7 Pages 21—29


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Radhika Kainthla,1 Kevin B Kim,2 Gerald S Falchook3

1Department of Internal Medicine, Baylor College of Medicine, 2Department of Melanoma Medical Oncology, 3Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract: Melanoma has the highest mortality of all the skin cancer subtypes. Historically, chemotherapy and immunologic therapies have yielded only modest results in the treatment of metastatic melanoma. The discovery of prevalent V600 BRAF mutations driving proliferation makes this oncogenic protein an ideal target for therapy. Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response rates and median progression-free survival in patients with V600E BRAF-mutant metastatic melanoma, including those with brain metastases. With a well-tolerated toxicity profile, dabrafenib is effective as a monotherapy; however, resistance eventually develops in almost all patients. As a result, current research is exploring the role of combination therapies with dabrafenib to overcome resistance.

Keywords: dabrafenib, metastatic melanoma, V600E BRAF mutation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]